Nutrition & Health OnLine Magazine: Latest Research

LATEST RESEARCH

By Davey Dunn

Effects of weekly administration of pegylated recombinant human OB protein on appetite profile and energy metabolism in obese men.

This study performed by researchers at Maastricht University in the Netherlands investigated the effectiveness of weekly injections of Leptin on decreasing bodyfat levels in obese men. BACKGROUND: Results of leptin administration in mice, rats, and humans provide a rationale for therapeutic augmentation of circulating leptin (OB protein) concentrations in obese humans; this may reduce food intake, increase metabolic rate, and lower body mass. OBJECTIVE: We assessed the effects of weekly subcutaneous pegylated polyethylene glycol (PEG)-OB protein administration on appetite and energy metabolism in obese men. DESIGN: We performed a randomized, double-blind, placebo-controlled trial in 30 obese men [body mass index (in kg/m(2)): 34.2 +/- 3.6; age: 44.7 +/- 7 y]. Subjects received 20 mg PEG-OB protein/wk for 12 wk while limiting their energy intake to 2.1 MJ/d. RESULTS: During treatment, appetite and hunger before breakfast decreased and remained lower in the PEG-OB-protein group, whereas they increased and remained higher in the placebo group (P < 0.0001). During treatment, hunger decreased in the PEG-OB-protein group (P < 0.05) and cognitive restraint increased in the placebo group (P < 0.0001). Neither appetite nor food intake changed significantly during the ad libitum evening meal. Under energy balance conditions in the respiration chamber, appetite at the end of treatment was not significantly different from baseline despite similar, significant reductions in 24-h energy intake, energy expenditure, sleeping metabolic rate, body mass, fat mass, and fat-free mass (P < 0.01 for all) in both groups. CONCLUSION: Treatment with PEG-OB protein modified subjective appetite at a dosage that produced no changes in body composition, energy expenditure, or body mass loss relative to placebo treatment, suggesting that PEG-OB protein has central rather than peripheral biological activity in obese men.

COMMENTARY: In 1995 researches found that when the hormone Leptin was given to obese rats they lost huge amounts of weight. Since then the mainstream media and the medical establishment have promised a solution to obesity based on this research with Leptin. Unfortunately all of the tests done on humans with Leptin have failed miserable. This study is just another example that early speculation about Leptin was premature and there will never be a "magic pill" for fat loss. This study also helps to show just how irresponsible pharmaceutical interests are to ever promise that they can produce a complete solution in pill form in the first place. When fat loss is based on the real science of Physics then the best you can ever hope from a pill would be as a supplement to a good diet and proper exercise.

WHAT CAN WE LEARN FROM THIS STUDY? Stop wasting time and money with useless presription drugs that do not work for losing bodyfat and can cause numerous other health problems.

Westerterp-Plantenga MS, Saris WH, Hukshorn CJ, Campfield LA. Am J Clin Nutr 2001 Oct;74(4):426-34

WEIGHT LOSS TIP OF THE DAY

May 14 ERROR: Can't connect to www.thermophenphen.com:80 (No route to host)

Editors View

Q's & A's

Lastest Research

Weight Loss Corner

E-Mail NHO

Front Page

InterNUTRITION

Disclaimer

This article was originally published by:
Nutrition & Health OnLine Magazine
URL: NHOmag.com
All articles available at Nutrition & Health OnLine Magazine may be re-published without prior permission as long as this box is included somewhere in the article and the article is unchanged and published in it's entirety. For further information contact:
NHOmag.com